OBJECTIVE: To review the antidepressant efficacy of S-Adenosyl-L-Methionine (SAMe) both in monotherapy and/or in augmentation with antidepressants to better understand its potential role in the treatment of patients with Major Depressive Disorder (MDD) and Treatment-Resistant Depression (TRD). DATA SOURCES: A MEDLINE/PubMed search was carried out by using the following set of keywords: ((SAMe OR SAdenosyl- L-Methionine) AND (major depressive disorder OR depression)). Data Selection and Data Extraction: No language or time restrictions were placed on the electronic searches. Randomized controlled trials and open trials involving humans were here included and analyzed. The references of published articles identified in the initial search process were also examined for any additional studies appropriate for the review. DATA SYNTHESIS: SAMe is an important physiologic compound, playing a central role as precursor molecule in several biochemical reactions. Numerous studies have shown that SAMe may affect the regulation of various critical components of monoaminergic neurotransmission involved in the pathophysiology of MDD. Some findings have suggested its antidepressant efficacy in treating MDD. Several randomized controlled trials have supported that the antidepressant efficacy of SAMe in monotherapy is superior to placebo and tricyclic antidepressants. Recent findings have also demonstrated its efficacy in patients nonresponsive to selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors. CONCLUSION: Overall, SAMe is a well-tolerated medication, which may offer considerable advantages as an alternative to antidepressant drugs or as an add-on therapy in the treatment of MDD and TRD. More large-scale controlled trials are needed to gain a better understanding of the relative efficacy of this drug.
OBJECTIVE: To review the antidepressant efficacy of S-Adenosyl-L-Methionine (SAMe) both in monotherapy and/or in augmentation with antidepressants to better understand its potential role in the treatment of patients with Major Depressive Disorder (MDD) and Treatment-Resistant Depression (TRD). DATA SOURCES: A MEDLINE/PubMed search was carried out by using the following set of keywords: ((SAMe OR SAdenosyl- L-Methionine) AND (major depressive disorder OR depression)). Data Selection and Data Extraction: No language or time restrictions were placed on the electronic searches. Randomized controlled trials and open trials involving humans were here included and analyzed. The references of published articles identified in the initial search process were also examined for any additional studies appropriate for the review. DATA SYNTHESIS: SAMe is an important physiologic compound, playing a central role as precursor molecule in several biochemical reactions. Numerous studies have shown that SAMe may affect the regulation of various critical components of monoaminergic neurotransmission involved in the pathophysiology of MDD. Some findings have suggested its antidepressant efficacy in treating MDD. Several randomized controlled trials have supported that the antidepressant efficacy of SAMe in monotherapy is superior to placebo and tricyclic antidepressants. Recent findings have also demonstrated its efficacy in patients nonresponsive to selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors. CONCLUSION: Overall, SAMe is a well-tolerated medication, which may offer considerable advantages as an alternative to antidepressant drugs or as an add-on therapy in the treatment of MDD and TRD. More large-scale controlled trials are needed to gain a better understanding of the relative efficacy of this drug.
Authors: Arun V Ravindran; Lynda G Balneaves; Guy Faulkner; Abigail Ortiz; Diane McIntosh; Rachel L Morehouse; Lakshmi Ravindran; Lakshmi N Yatham; Sidney H Kennedy; Raymond W Lam; Glenda M MacQueen; Roumen V Milev; Sagar V Parikh Journal: Can J Psychiatry Date: 2016-08-02 Impact factor: 4.356
Authors: Hitoshi Sakurai; Linda L Carpenter; Audrey R Tyrka; Lawrence H Price; George I Papakostas; Christina M Dording; Albert S Yeung; Cristina Cusin; Elizabeth Ludington; Richard Bernard-Negron; Maurizio Fava; David Mischoulon Journal: J Affect Disord Date: 2019-10-31 Impact factor: 4.839
Authors: Jin Gao; Catherine M Cahill; Xudong Huang; Joshua L Roffman; Stefania Lamon-Fava; Maurizio Fava; David Mischoulon; Jack T Rogers Journal: Neurotherapeutics Date: 2018-01 Impact factor: 7.620
Authors: Olga V Averina; Yana A Zorkina; Roman A Yunes; Alexey S Kovtun; Valeriya M Ushakova; Anna Y Morozova; George P Kostyuk; Valery N Danilenko; Vladimir P Chekhonin Journal: Int J Mol Sci Date: 2020-12-03 Impact factor: 5.923
Authors: Petra Prochazkova; Radka Roubalova; Jiri Dvorak; Jakub Kreisinger; Martin Hill; Helena Tlaskalova-Hogenova; Petra Tomasova; Helena Pelantova; Martina Cermakova; Marek Kuzma; Josef Bulant; Martin Bilej; Kvido Smitka; Alena Lambertova; Petra Holanova; Hana Papezova Journal: Gut Microbes Date: 2021 Jan-Dec